Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on July 11, 2009
Japanese Journal of Clinical Oncology 2009 39(10):651-656; doi:10.1093/jjco/hyp076
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
39/10/651    most recent
hyp076v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Toyama, T.
Right arrow Articles by Fujii, Y.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Toyama, T.
Right arrow Articles by Fujii, Y.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author (2009). Published by Oxford University Press. All rights reserved

No Association Between CYP2D6*10 Genotype and Survival of Node-negative Japanese Breast Cancer Patients Receiving Adjuvant Tamoxifen Treatment

Tatsuya Toyama1, Hiroko Yamashita1, Hiroshi Sugiura1, Naoto Kondo1, Hirotaka Iwase2 and Yoshitaka Fujii1

1 Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, Nagoya
2 Department of Breast and Endocrine Surgery, Kumamoto University Graduate School of Medical Sciences, Kumamoto, Japan

For reprints and all correspondence: Tatsuya Toyama, Department of Oncology, Immunology and Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya 467-8601, Japan. E-mail: t.toyama{at}med.nagoya-cu.ac.jp

Received April 27, 2009; accepted June 5, 2009

Objective: The CYP2D6 enzyme plays a major role in converting tamoxifen to its active metabolites. We investigated whether there is an association between the CYP2D6*10 allele and clinical outcome in node-negative Japanese breast cancer patients.

Methods: CYP2D6 genotyping was performed in 154 node-negative breast cancer patients who had received adjuvant tamoxifen treatment alone. The CYP2D6 genotypes were determined using the TaqMan Allelic Discrimination Assay.

Results: Eighteen percent (28 of 154) of the patients carried the CYP2D6*10/*10 genotype, 40% the CYP2D6 wild-type (wt)/*10 genotype and 42% the CYP2D6 wt/wt genotype. There were no discernible correlations between clinicopathologic parameters and the CYP2D6*10 genotype. Next, we determined whether there was a correlation between the CYP2D6*10 genotype and survival and found that the clinical outcome for patients carrying the CYP2D6*10/*10 genotype was similar to those with other genotypes.

Conclusions: Our results suggest that the CYP2D6*10 genotype is unlikely to have any clinical significance for prognosis of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen alone.

Key Words: CYP2D6 • CYP2D6*10 • breast cancer • tamoxifen


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.